BEIJING, Dec. 18, 2013 (GLOBE NEWSWIRE) -- Dehaier Medical Systems Ltd. (Nasdaq:DHRM) ("Dehaier" or the "Company"), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, announced today that it has successfully bid on a large-scale medical equipment procurement valued at approximately $600,000 (RMB 3.7 million). Dehaier's bid to provide Cardiac Color Doppler Ultrasonic Diagnostic Apparatus medical equipment was its successful bid with the Beijing Kanglian Medical Company. Under the bid, Dehaier will provide medical equipment to rural hospitals and clinics in Shanxi Province under China's New Rural Infrastructure Project. The Project is supported by the China Development Bank, one of China's three national policy banks.
"State-level medical device procurement is one of our strategic foci," Mr. Ping Chen, CEO and chairman of Dehaier Medical said. "Meanwhile, we will continue to maintain our traditional medical business, and promote growth in our sleep apnea and oxygen therapy business. We believe these goals are key to our success over the near term."
About Dehaier Medical Systems Ltd.
Dehaier Medical Systems is an emerging leader in the development, assembly, marketing and sale of medical products in China, including respiratory and oxygen homecare medical products. The company develops and assembles its own branded products from third-party components. The company also distributes products designed and manufactured by other companies, including medical devices and respiratory and oxygen homecare products from IMD (Italy), Welch Allyn (USA), Penlon (UK), HEYER (Germany), Timesco (UK), ResMed (Australia), and JMS (Japan). Dehaier's technology is based on two patents, five pending patents, and proprietary technology. More information may be found at www.dehaier.com.cn.
Forward-looking Statements
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, fulfillment of bids and contracts, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.